15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 3 firms covering Akebia Ther, 3 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets span $4.00 to $6.00, a moderate spread. The average target of $4.67 sits 262% above the current $1.29. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees revenue growth near -13% this year and -23% next, consensus EPS building from about $-0.03 next quarter toward $-0.19 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 ratings
Moderate Buy
Strong Buy00%
Buy3100%
Hold00%
Sell00%
Strong Sell00%
Based on 3 analysts giving stock ratings to Akebia Ther.
As of Jul, 3 of 3 firms rate AKBA a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
AKBA EPS & revenue forecast
EPS · NEXT QUARTER
$-0.03
Range $-0.04 – $-0.02 · 2 analysts
Next period, 2 analysts expect Akebia Ther to earn $-0.03 a share (range $-0.04 – $-0.02), versus $0.00 a year earlier. Full-year consensus is $-0.10, growing to $-0.19 the year after.
REVENUE · NEXT QUARTER
$49.8M
Range $39.5M – $54.6M · 2 analysts · -15% YoY
Revenue is expected to reach $49.8M (range $39.5M – $54.6M), -15.0% year-over-year. Full-year consensus is $206.6M, rising to $159.9M next year.
Top analysts covering Akebia Ther
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on AKBA.
#1
MC
Matthew Caufield
HC Wainwright & Co. · Rank #51
Buy
$6.00+365.1% to target
Overall win rate
56%
+ Follow
#2
Ed Arce
HC Wainwright & Co. · Rank #107
Buy
$7.50+481.4% to target
Overall win rate
44%
+ Follow
#3
Julian Harrison
BTIG
Buy
$4.00+210.1% to target
Coverage
—
+ Follow
#4
Allison Bratzel
Piper Sandler
Buy
$4.00+210.1% to target
Coverage
—
+ Follow
#5
Roanna Ruiz
SVB Leerink
Buy
$7.00+442.6% to target
Coverage
—
+ Follow
AKBA stock forecast FAQ
What is AKBA's average 12-month price target?+
The 3 analysts with a live target average $4.67 for Akebia Ther over the next 12 months, ranging from a $6.00 high to a $4.00 low.
Is AKBA stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 3 analyst ratings, 3 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for AKBA?+
The Street-high target is $6.00 (HC Wainwright & Co.), and the Street-low is $4.00 (BTIG). The average of all 3 active targets is $4.67.
How many Wall Street analysts cover AKBA?+
3 analysts have an active rating on Akebia Ther, and 3 firms carry a live 12-month price target.
Who is the most accurate analyst covering AKBA?+
Among analysts who currently cover AKBA, Matthew Caufield of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #51). Their current call is Buy with a $6.00 target.
What is Akebia Ther's projected EPS for next quarter?+
The consensus estimate is $-0.03 per share (range $-0.04 – $-0.02) across 2 analysts. Full-year EPS is projected at $-0.10, rising to $-0.19 the following year.
How much revenue is Akebia Ther expected to report next quarter?+
Consensus revenue is $49.8M (range $39.5M – $54.6M). Full-year revenue is projected at $206.6M, growing to $159.9M next year.
Have analysts been upgrading or downgrading AKBA lately?+
As of Jul, 3 of 3 firms rate AKBA a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their AKBA calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
